Amphastar Pharmaceuticals, Inc. (AMPH)
25.43
+0.08
(+0.32%)
USD |
NASDAQ |
Oct 02, 16:00
25.44
+0.01
(+0.04%)
After-Hours: 20:00
Amphastar Pharmaceuticals Enterprise Value : 1.477B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.477B |
| October 01, 2026 | 1.474B |
| September 30, 2026 | 1.494B |
| September 29, 2026 | 1.531B |
| September 28, 2026 | 1.561B |
| September 25, 2026 | 1.507B |
| September 24, 2026 | 1.513B |
| September 23, 2026 | 1.457B |
| September 22, 2026 | 1.430B |
| September 21, 2026 | 1.437B |
| September 18, 2026 | 1.400B |
| September 17, 2026 | 1.409B |
| September 16, 2026 | 1.414B |
| September 15, 2026 | 1.401B |
| September 14, 2026 | 1.413B |
| September 11, 2026 | 1.407B |
| September 10, 2026 | 1.397B |
| September 09, 2026 | 1.376B |
| September 08, 2026 | 1.371B |
| September 04, 2026 | 1.382B |
| September 03, 2026 | 1.410B |
| September 02, 2026 | 1.405B |
| September 01, 2026 | 1.372B |
| August 31, 2026 | 1.354B |
| August 28, 2026 | 1.332B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.326B |
| August 26, 2026 | 1.332B |
| August 25, 2026 | 1.331B |
| August 24, 2026 | 1.311B |
| August 21, 2026 | 1.314B |
| August 20, 2026 | 1.318B |
| August 19, 2026 | 1.320B |
| August 18, 2026 | 1.303B |
| August 17, 2026 | 1.283B |
| August 14, 2026 | 1.285B |
| August 13, 2026 | 1.254B |
| August 12, 2026 | 1.246B |
| August 11, 2026 | 1.264B |
| August 10, 2026 | 1.260B |
| August 07, 2026 | 1.280B |
| August 06, 2026 | 1.238B |
| August 05, 2026 | 1.257B |
| August 04, 2026 | 1.242B |
| August 03, 2026 | 1.256B |
| July 31, 2026 | 1.244B |
| July 30, 2026 | 1.263B |
| July 29, 2026 | 1.271B |
| July 28, 2026 | 1.253B |
| July 27, 2026 | 1.212B |
| July 24, 2026 | 1.192B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viatris, Inc. | 32.55B |
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| Pfizer Inc. | 210.23B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 30.35M |
| Revenue (Quarterly) | 183.90M |
| Total Expenses (Quarterly) | 153.56M |
| EPS Diluted (Quarterly) | 0.6862 |
| Gross Profit Margin (Quarterly) | 48.73% |
| Profit Margin (Quarterly) | 16.50% |
| Earnings Yield | 6.71% |
| Operating Earnings Yield | 9.69% |
| Normalized Earnings Yield | 5.941 |